GILL SIMBA 4

What Happened
Gill Simba, a member of Foghorn Therapeutics' board of directors, was granted a derivative award on 2026-06-24 covering 28,000 shares with an associated price of $4.08, reflecting a grant value of $114,240. This was an award/grant (not an open-market purchase or sale) — specifically an option award per the filing footnote — which is typically a compensation/retention vehicle rather than an outright cash purchase.

Key Details

• Transaction date: 2026-06-24; Form 4 filed 2026-06-25 (timely filing).
• Award: 28,000 derivative shares at $4.08; total recorded value $114,240.
• Security type: Option grant (derivative); footnote confirms it is an option.
• Vesting: Option vests in full on the first anniversary of the grant date, subject to continued board service (footnote F1).
• Shares owned after transaction: Not disclosed in this filing.
• Filing timeliness: No late filing indicated.

Context

• This transaction is an award of options to a director (compensation/retention), not an open-market buy or sale; such grants are common for board service and do not by themselves signal insider buying or selling intent.
• For investors, option grants are useful to track but only become economically meaningful if the stock price rises above the option exercise price and/or the options are exercised and shares sold later.